Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enterocloster bolteae
- Development stage
- Unknown
- Lead developer
- Vedanta Biosciences
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Enterocloster bolteae (formerly Clostridium bolteae) is a Gram-positive, anaerobic bacterium belonging to the Clostridia cluster XIVa. It is being developed by Vedanta Biosciences as a key component of VE303, a defined bacterial consortium for the prevention of recurrent Clostridioides difficile infection (CDI). E. bolteae contributes to the therapeutic effect through colonization resistance, which involves competing with C. difficile for limited nutrients and producing metabolites such as short-chain fatty acids (SCFAs) that inhibit the growth and toxin production of the pathogen. Additionally, members of Clostridia cluster XIVa are known to induce the expansion of regulatory T cells (Tregs) in the gut, potentially modulating local inflammation and supporting intestinal homeostasis. VE303, which includes E. bolteae as one of its eight constituent strains, has demonstrated efficacy in Phase 2 clinical trials and is advancing into Phase 3 development.
- Other names
- Clostridium bolteaeEnterocloster bolteae (Clostridia cluster XIVa), live
02
Targets
DSG1 (Desmoglein-1)
Beyond the preview
Go deeper on enterocloster bolteae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enterocloster bolteae.